Atara Biotherapeutics Inc (NAS:ATRA)

$ 10.28 -1.35 (-11.61%) Market Cap: 58.33 Mil Enterprise Value: 83.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Atara Biotherapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Atara Biotherapeutics Inc Earnings Call Transcript
Nov 01, 2023

$31.5 (-2.33%)

Earnings
Atara Biotherapeutics Inc at Citi BioPharma Conference Transcript
Sep 07, 2023
Atara Biotherapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Atara Biotherapeutics Inc at Cowen Health Care Conference Transcript
Mar 08, 2023
Atara Biotherapeutics Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Feb 28, 2023
Atara Biotherapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 Atara Biotherapeutics Inc Earnings Call Transcript
Nov 08, 2022

$122.5 (+3.59%)

Earnings
Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel Transcript
Sep 07, 2022
Q2 2022 Atara Biotherapeutics Inc Earnings Call Transcript
Aug 08, 2022

$90.75 (+5.52%)

Earnings
Atara Biotherapeutics Inc To Announce Completion of ATA188 Phase 2 EMBOLD Study Transcript
Jul 12, 2022
Q1 2022 Atara Biotherapeutics Inc Earnings Call Transcript
May 05, 2022

$170.5 (-6.70%)

Earnings
Atara Biotherapeutics Inc EBV and MS Day Transcript
Mar 22, 2022
Q4 2021 Atara Biotherapeutics Inc Earnings Call Transcript
Feb 28, 2022

$321.25 (-2.58%)

Earnings
Atara Biotherapeutics Inc T-Cell Operations and Manufacturing (ATOM) Facility Acquisition by FUJIFILM Diosynth Biotechnologies (FDB) Transcript
Jan 27, 2022
Atara Biotherapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Q3 2021 Atara Biotherapeutics Inc Earnings Call Transcript
Nov 04, 2021

$497.25 (+6.08%)

Earnings
Atara Biotherapeutics Inc to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021 Transcript
Oct 13, 2021
Atara Biotherapeutics Inc and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel Corporate Call Transcript
Oct 04, 2021
Atara Biotherapeutics Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Atara Biotherapeutics Inc Earnings Call Transcript
Aug 09, 2021

$312.25 (-1.19%)

Earnings
Atara Biotherapeutics Inc at Cowen Virtual Oncology Innovation Summit Transcript
May 20, 2021
Q1 2021 Atara Biotherapeutics Inc Earnings Call Transcript
May 04, 2021

$341.25 (-2.85%)

Earnings
Q4 2020 Atara Biotherapeutics Inc Earnings Call Transcript
Mar 01, 2021

$427.63 (+1.94%)

Earnings
Atara Biotherapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Atara Biotherapeutics Inc Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Transcript
Jan 04, 2021
Atara Biotherapeutics, Inc. - Special Call Transcript
Dec 07, 2020
Atara Biotherapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
Dec 02, 2020
Q3 2020 Atara Biotherapeutics Inc Earnings Call Transcript
Nov 09, 2020

$360 (+7.06%)

Earnings
Atara Biotherapeutics, Inc. - Special Call Transcript
Sep 11, 2020
Q2 2020 Atara Biotherapeutics Inc Earnings Call Transcript
Aug 05, 2020

$317.75 (+3.17%)

Earnings
Atara Biotherapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2020
Atara Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Atara Biotherapeutics, Inc. - Special Call Transcript
May 26, 2020
Q1 2020 Atara Biotherapeutics Inc Earnings Call Transcript
May 06, 2020

$212.5 (-2.52%)

Earnings
Atara Biotherapeutics Inc at Barclays Global Healthcare Conference Transcript
Mar 11, 2020
Atara Biotherapeutics Inc at Cowen HealthCare Conference Transcript
Mar 02, 2020
Q4 2019 Atara Biotherapeutics Inc Earnings Call Transcript
Feb 27, 2020

$287 (+2.78%)

Earnings
Atara Biotherapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Q3 2019 Atara Biotherapeutics Inc Earnings Call Transcript
Nov 07, 2019

$338 (+11.18%)

Earnings
Atara Biotherapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa Transcript
Oct 02, 2019
Atara Biotherapeutics Inc ECTRIMS Conference Call Transcript
Sep 13, 2019
Atara Biotherapeutics Inc at Citi Biotech Conference Transcript
Sep 04, 2019
Q2 2019 Atara Biotherapeutics Inc Earnings Call Transcript
Aug 08, 2019

$313.5 (+4.24%)

Earnings
Atara Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 13, 2019
Atara Biotherapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 05, 2019
Q1 2019 Atara Biotherapeutics Inc Earnings Call Transcript
May 09, 2019

$680.5 (-20.60%)

Earnings
Atara Biotherapeutics Inc at Cowen Health Care Conference Transcript
Mar 12, 2019

Atara Biotherapeutics Inc To Announce Completion of ATA188 Phase 2 EMBOLD Study Transcript

Jul 12, 2022 / 09:00PM GMT

Release Date Price: $216.5 (+17.03%)

Transcript

Operator

Good afternoon, everyone. Thank you for standing by, and welcome to the Atara Biotherapeutics ATA188 Interim Analysis Disclosure Conference Call. (Operator Instructions) Please be advised that today's call is being recorded. I'd now like to hand the call over to Eric Hyllengren, Vice President of Investor Relations and Finance at Atara Biotherapeutics. Please go ahead, sir.

Eric Hyllengren

Atara Biotherapeutics, Inc. - VP of IR & Finance

Thank you, Laura. Good afternoon, everyone, and welcome to Atara's ATA188 EMBOLD Study Interim Analysis Disclosure Conference Call. Earlier today, we issued a press release announcing completion of the ATA188 Phase II EMBOLD interim analysis in patients with progressive multiple sclerosis. This press release is available in the Investors and Media section at atarabio.com.

On today's call, members from the Atara executive team will provide an update on the Phase II EMBOLD study for ATA188 and also answer any questions you may have. Joining me on today's call are Dr. Pascal Touchon, President and Chief Executive

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.